WHAT WE DO

Zelaris Ventures

Building the Pipeline for Tomorrow’s Cures We are architects of the future of medicine, actively building our investment portfolio for a dedicated life sciences fund. While we secure our capital, our focus is on forging early, strategic alliances with the most promising Pre-Series A and Series A companies in the life sciences ecosystem. Our Mission: Strategic Sourcing & Founder Partnership We identify and deeply vet visionary founders developing transformative therapies, platforms, and technologies. For a select group of pioneers, we engage in a pre-investment partnership, providing strategic counsel to strengthen their operational readiness and investment narrative.
  • Active Deal Sourcing: Identifying and vetting high-potential life science startups.
  • Strategic Capital Introduction: Connecting validated startups with our network of institutional investors.
  • We are actively scouting for companies pioneering:
  1. AI Algorithms for Therapeutic Platforms
  2. Medicinal Modalities (Cell & Gene Therapies, mRNA, etc.)
  3. Enabling Technologies for Drug Development and Manufacturing (AI powered clinical trials management, bioprocessing tech, algorithms to predict the rate of commercial success etc.)
  4. AI powered med tech, health tech, wearable tech, life sciences tools (algorithms, novel technologies, etc.)

For Founders:
If you are building the future of medicine and believe in the power of a strategic alliance to prepare for scale, we should speak.
Contact the venture team at zein@zelarisventures.com.

Consulting Engagement Steps

01

Understand deliverables, milestones and pain points

Once a Disclosure Agreement (CDA) is signed, we work with you to map out project pain points and goals.

02

Work with industry experts

Our industry expert leaders will map out strategy, budget and meet with you to review.

03

Execute Project

We get to work, while keeping you in the loop on milestone progress.

04

Handover

You will meet with our expert leaders to review and process the final handover. We are available for post-handover questions and guidance.